In small molecule drug development, unexpected crystal forms can significantly impact a drug's stability, manufacturability, and bioavailability, leading to costly delays and potential failures in the formulation process. Traditional methods for identifying and characterizing crystal structures are often time-consuming and resource-intensive.

Lavo Life Sciences offers an AI-powered crystal structure prediction platform designed to accelerate and de-risk small molecule drug development. The platform enables pharmaceutical teams to rapidly and accurately identify potential crystal forms of drug candidates, minimizing the risk of encountering unforeseen issues related to solid-state properties. By predicting crystal structures early in the development pipeline, Lavo Life Sciences helps optimize drug formulations for enhanced stability, manufacturability, and bioavailability. The technology facilitates the discovery of novel polymorphs with improved properties, ultimately streamlining the drug development process and reducing the likelihood of late-stage surprises.

AI-driven algorithms for rapid and accurate crystal structure prediction

Identification of potential crystal forms to mitigate risks associated with solid-state properties

Optimization of drug formulations for enhanced stability and manufacturability

Discovery of novel polymorphs with improved drug properties

Computational chemistry tools to accelerate the drug development process

The primary target audience includes pharmaceutical companies, drug development teams, and research institutions involved in small molecule drug discovery and formulation.